Estimation of hERG inhibition of drug candidates using multivariate property and pharmacophore SAR

被引:24
作者
Johnson, Stephen R.
Yue, Hongwen
Conder, Mary Lee
Shi, Hong
Doweyko, Arthur M.
Lloyd, John
Levesque, Paul
机构
[1] Bristol Myers Squibb Co, Comp Assisted Drug Design, Princeton, NJ 08543 USA
[2] Bristol Myers Squibb Co, Discovery Toxicol, Princeton, NJ 08543 USA
[3] Bristol Myers Squibb Co, Discovery Biol, Princeton, NJ 08543 USA
[4] Bristol Myers Squibb Co, Med Chem, Princeton, NJ 08543 USA
关键词
hERG; novelty detection; pharmacophore model; prolonged QTc; QSAR; in silico;
D O I
10.1016/j.bmc.2007.06.028
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We describe the development of a computational model for the prediction of the inhibition of K+ flow through the hERG ion channel. Using a collection of 1075 discovery compounds with hERG inhibition measured in our standard patch-clamp electrophysiology assay, molecular features important for drug-induced inhibition were identified using a combination of statistical inference algorithms and manual hypothesis generation and testing. While many of the features used in the model reflect those referenced in the literature, several aspects of the model provide new insight into the role of physicochemical properties, electrostatics, and novel pharmacophores in hERG inhibition. Coefficients for these 10 features were then determined by least median squares regression, resulting in a model with an R-2 similar to 0.66 and RMS error (RMSe) of 0.47 log units for an external test set. Significant additional validation performed using a large collection of subsequent discovery data has been very encouraging with an R-2 = 0.54 and an RMSe of 0.63 log units. The performance of the model across several different chemotypes is demonstrated and discussed. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6182 / 6192
页数:11
相关论文
共 66 条